Starlight Success: Isis, Alnylam Form Regulus To Develop MicroRNA Antagonists
Firm’s lead molecule, miR-122, could be in clinic to treat hepatitis C within two to three years, Isis CEO tells “The Pink Sheet” DAILY.
Firm’s lead molecule, miR-122, could be in clinic to treat hepatitis C within two to three years, Isis CEO tells “The Pink Sheet” DAILY.